President's Message

History of Challenges

Taiho Pharmaceutical Co., Ltd. was established as a member of the Otsuka group in 1963. Ever since, the whole company has worked as a united team to provide quality products that people around the world can use with confidence and to disseminate safety information. Looking back over the history of the company’s pharmaceutical business since its establishment, we recall the 1974 Japan launch of Futraful, an oral tegafur formulation, one of the world’s first oral anticancer agents. This was followed by the Japan launches of other oral anticancer agents developed in-house: UFT (a formulation of tegafur and uracil) in 1984, TS-1 (a formulation of tegafur, gimeracil, and oteracil potassium) in 1999, and LONSURF (trifluridine and tipiracil) in 2014. In 2015, LONSURF became the first Taiho product to be marketed directly by the company in the U.S. In 2016, the drug was launched in Europe via our French partner, Servier. Today, it is available in an increasing number of countries around the world.
Each of these examples shows how Taiho Pharmaceutical has continued to embrace the challenge of developing medicines that can contribute to cancer chemotherapy around the world. Meanwhile, we have also worked intensively on the development of innovative pharmaceuticals in the allergy, immunology, and urology fields. We are continuing to do everything we can to create new drugs that help to improve quality of life for patients and contribute to full recovery. The company has also developed muchloved brands in the consumer healthcare market, like Tiovita, Solmack and Harncare. We are determined to continue to take on the challenge of creating and nurturing unique brands that people love for many years.

Spirit of Globalization

Taiho Pharmaceutical is focusing on reinforcing its marketing structure in North America, Asian countries, Europe and other markets in order to give patients all around the world access to its products. We are also conducting numerous global clinical trials via existing clinical development centers in Japan as well as in Europe, the U.S. and Asia. We are pursuing simultaneous global development of a number of promising compounds coming out of our R&D divisions, seeking to get these new drugs ready for patients around the world as soon as possible. The most important thing for our business development will be securing people with great talent. We develop world-class human resources, bring in top talent without regard for nationality or other such factors, and actively promote work-style reform. In addition, we provide work support for employees who have cancer or other diseases. Taiho Pharmaceutical creates optimal workplaces where people from diverse backgrounds can truly enjoy their jobs.

Commitment to Compliance

In line with Taiho Pharmaceutical’s corporate philosophy—“We strive to improve human health and contribute to a society enriched by smiles.”— each and every employee strives to ensure compliance. Our people take the company’s close involvement with human life seriously and understand the importance of complying with the letter and spirit of the law and codes of conduct. Going forward, our entire team will work as one (Global One Taiho) to pursue sustainability in order to ensure that Taiho Pharmaceutical remains a valuable contributor to the health of people worldwide by developing and supplying outstanding pharmaceuticals.

Masayuki Kobayashi
President and Representative Director